Clinical Trial Update: Universal Cancer Peptide-based Vaccination in Metastatic NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial of a universal cancer peptide-based vaccination for metastatic non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Centre Hospitalier Universitaire de Besancon | Conditions: Metastatic Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED